Pre‐transplant level of soluble CD30 is associated with infection after heart transplantation

Abstract

We report for the first time that the high level of sCD30 prior to the HTx may be associated with a higher immunologic ability of the pts and therefore, may have a protective effect in the development of infection post-Tx.

Soluble CD30 Levels in Recipients Undergoing Heart Transplantation Do Not Predict Post-transplant Outcome

“…These results contrast with those of Frisaldi et al, 15 who suggested that pre-transplant serum sCD30 levels Ͼ30 U/ml were associated with reduced recipient survival, whereas, in the present study, sCD30 levels were not predictive of allograft rejection. Our findings are consistent with those of Spiridon et al 16 and Nikaein et al,17 who reported that high serum sCD30 had no effect on overall patient survival, although the latter group noted that serum sCD30 levels Ն90 U/ml were associated with a reduction in post-transplant infection rate.…”

“…[5][6][7][8][9] However, the utility of sCD30 as a predictor for renal transplant outcome has not been supported by all studies, 10 -14 and there is little information as to whether pretransplant levels of sCD30 are predictive of outcome after cardiac transplantation. [15][16][17] Herein we report the results of a large single-center study evaluating the clinical usefulness of pre-transplant serum sCD30 levels as a prognostic marker of heart allograft rejection and recipient survival.…”

Lymphocyte surface molecules as immune activation biomarkers

“…The nonrenal transplant recipient data are very limited. Although the marker has been investigated as an outcome predictor, for example, in heart, lung, islet, and liver [67][68][69][70] transplantations, these studies were smaller and their outcomes were contradictory. As for kidney transplantation, unresolved issues regarding the optimal time points for sCD30 determinations as well as the appropriate cut-offs remain.…”

Defining unacceptable HLA antigens

“…Early, aggressive rejection of a previous transplant that is unexplained by other factors such as inadequate immunosuppression, suggests a more aggressive responder type. Elevated pretransplant levels of soluble CD30 have been associated with increased risk of rejection and graft loss [17][18][19]. There have been conflicting reports of an association between cytokine genotypes and responsiveness, although, perhaps when combined with other factors, cytokine genotype information may add to the description of responder type [20].…”